NCT05466201View on ClinicalTrials.gov

The Use of Eltrombopag Post HSCT in BMFS

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 22, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2027

Conditions
Stem Cell Transplant Complications
Interventions
DRUG

Eltrombopag 25 MG Oral Tablet

Since thrombopoietin receptor agonists (TPO-RAs) have never been regularly used for promotion of cell engraftment post hematopoietic stem cell transplantation HSCT), we design this eltrombopag intervention to evaluate the safety and efficacy of TPO-RAs post HSCT.

DRUG

Supportive care

Patients receive transfusion of blood products, including platelets and red blood cells.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER